Xi Chen

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, Feng Bi, Shanzhi Gu et al. · Journal of Clinical Oncology · 2021 · 414 citations · Full text

Pharmacy, Oncology, Pharmacology +14

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 254 citations

Medicine, Oncology, Pharmacotherapy +10

Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer

Linfeng Xian, Pei Zhao, Xi Chen et al. · Cellular Oncology · 2022 · 58 citations · Full text

Medicine, Cancer Biology, Oncology +15

Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis

Lei Liu, Yan Zhao, Xingshun Qi et al. · Hepatology Research · 2013 · 44 citations

Medicine, Oncology, Surgery +17